Linzagolix, CAS [[935283-04-8]]

Catalog Number: TGM-T27837
Article Name: Linzagolix, CAS [[935283-04-8]]
Biozol Catalog Number: TGM-T27837
Supplier Catalog Number: T27837
Alternative Catalog Number: TGM-T27837-1MLX10MM(INDMSO),TGM-T27837-1MG,TGM-T27837-5MG,TGM-T27837-10MG,TGM-T27837-25MG,TGM-T27837-50MG
Manufacturer: TargetMol
Category: Biochemikalien
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Molecular Weight: 508.42
Purity: 99.68%
CAS Number: [935283-04-8]
Formula: C22H15F3N2O7S
Target: GNRH Receptor
T27837